investigate the association of PCK1 polymorphisms with metabolic traits in psychiatric patients treated 23
with psychotropic drugs inducing weight gain and in general population samples. One polymorphism
24
(rs11552145G>A) significantly associated with Body Mass Index in the psychiatric discovery sample 25 (n=478) was replicated in 2 other psychiatric samples (n1=168, n2=188), with AA-genotype carriers having 26 lower Body Mass Index as compared to G-allele carriers. Stronger associations were found among 27 women younger than 45 years carrying AA-genotype as compared to G-allele carriers (-2.25 kg/m 2 , 28 n=151, p=0.009) and in the discovery sample (-2.20 kg/m 2 , n=423, p=0.0004). In the discovery sample for 29 which metabolic parameters were available, AA-genotype showed lower waist circumference (-6.86 cm, 30 p=0.008) and triglycerides levels (-5.58 mg/100mL, p<0.002) when compared to G-allele carriers. Finally, 31 waist to hip ratio was associated with rs6070157 (proxy of rs11552145, r 2 =0.99) in a population-based 32 sample (N=123'865, p=0.022). Our results suggest an association of rs11552145G>A polymorphism with 33 metabolic-related traits, especially in psychiatric populations and in women younger than 45 years old.
INTRODUCTION

35
Weight gain is a known side-effect of psychotropic drugs such as antipsychotics, mood stabilizers and 36 antidepressants. 1 Psychotropic-induced weight gain can lead to many metabolic complications (e.g.
37
increase in triglycerides, cholesterol, waist circumference) and is related to comorbidities such as 38 diabetes, hypertension and other cardiovascular diseases. 2 Psychiatric populations have a 10 to 25 year 39 reduction in life expectancy due to comorbidities and to the psychiatric illness itself, corresponding to a 2-40 3 fold increased mortality rate when compared to healthy populations. 3 Obesity is attributed to the 41 psychiatric illness, to behavioral and environmental factors (i.e. diet, exercise, smoking), as well as 42 genetic factors. 4 Besides, an interaction between genetic factors and psychotropic drug inducing weight 43 gain has been described implicating several receptors (e.g. serotonin and dopamine receptors) and 44 hormones (e.g. leptin) involved in energy balance or metabolism pathways. 5, 6 45 The Phosphoenolpyruvate carboxykinase (PCK) gene codes for an enzyme involved in the 46 gluconeogenesis 7 and is found in two forms, PCK1 (cytosolic) and PCK2 (mitochondrial). Both enzymes 47 are expressed equally in the liver but their expression may vary depending on the tissue. 7, 8 PCK 48 catalyzes the conversion from oxalacetate into phosphoenolpyruvate (a rate-controlling step of 49 gluconeogenesis) and is also involved in glyceroneogenesis and cataplerosis. 7 Of note, PCK is a 50 downstream gene of the CREB-regulated transcription coactivator 1 (CRTC1) which is implicated in 51 hypothalamic control of food intake 9, 10 and we recently found in general and psychiatric populations that carriers of a variant allele of a CRTC1 polymorphism appear to be protected against weight gain 53 especially in women younger than 45 years old. 11 
54
Rodents who over-express PCK1 and PCK2 were obese, hyperglycemic and insulin resistant 12, 13 55 whereas mice that under-expressed PCK1 and PCK2 developed a lipodistrophy type of metabolic 56
syndrome. 14 This is in line with the positive correlation found between PCK1 mRNA expression levels and
57
Body Mass Index (BMI), body fat percentage, triglycerides (TG) and cholesterol (CHOL) levels in 58 subcutaneous adipose tissue of non-menopausal women. 15 In humans, regions near PCK1 locus have 59 been related to obesity or fat mass 16, 17 and several positive associations have been reported between 60 PCK1 polymorphisms and type 2 diabetes 18-20 although these results could not always be replicated. 21 
61
Other studies conducted in the general population showed no significant association between PCK1 62 polymorphisms and BMI, waist circumference (WC) or physical activity. 22 A case-control study in a 63 diabetic versus non diabetic population also found that non diabetic homozygous for the minor allele of a 64 PCK1 polymorphism (+4824T>C) had increased levels of high density lipoproteins (HDL) and lower TG 65 levels when compared to wild type. 23 Thus growing evidence supports that PCK contributes to obesity 66 and metabolic syndrome in the general population but, to our knowledge, no studies have yet been 67 conducted in psychiatric populations which are at high risk for developing obesity and metabolic 68 syndrome. The aim of the present study was to analyze whether PCK1 polymorphisms were associated 69 with BMI and other metabolic traits (i.e. WC, blood glucose levels (BGL), low density lipoprotein (LDL), HDL, CHOL and TG in three independent psychiatric populations treated with drugs inducing weight gain 71 and in 3 large general population cohorts. As a secondary aim, we wanted to explore how PCK1 and 72 CRTC1 polymorphisms are associated with BMI in a combined analysis. 73
MATERIALS AND METHODS
74
Psychiatric sample description
75
The first psychiatric sample (discovery sample) was recruited during a longitudinal follow-up study on 
99
treatment was self-reported or extracted from medical files. As shown previously, 11 self-reported weight 100 was found to be a reliable estimate of the measured weight extracted from medical files.
101
In all samples, patients with previous treatments were included after having switched medication. The 102 latest introduced psychotropic medication was considered as the main psychotropic treatment. Weight
103
(patients with light clothes and without shoes) was measured in kilograms to the nearest kg. Height was 104 measured using a height gauge to the nearest cm. WC was measured to the nearest cm. BMI for all Written informed consent was provided by all individuals or by their legal representatives and the studies 107 were approved by the ethics committee of the corresponding centers. Further details of the 3 psychiatric 108 cohorts have already been described elsewhere. 11, 26 Of note, the present study refers to the same 3 109 psychiatric populations than in our previous paper, 11 but with a larger number of patients included in the 110 discovery cohort and in the replication sample 2 (inclusions ongoing). In a first step, the best replicated and studied PCK1 polymorphism in the literature (i.e. rs2071023) was 123 manually genotyped using TaqMan allelic discrimination assay (ABI PRISM 7000 Sequence Detection
124
System; Applied Biosystems, Rotkreuz, Switzerland, TaqMan SNP genotyping assays ID: C 2508731 1).
125
Additionally, three SNPS which were available in the CardioMetaboChip were also considered for 126 analysis (i.e. rs11552145, rs707555 and rs8123020 genotypes were grouped and analyzed in recessive (for rs11552145, rs707555 and rs8123020) and 147 dominant (for rs2071023) models according to their association with BMI showed in preliminary analyses. 148
Other covariates were extracted from medical files or during the interview and included demographic data 149 (i.e. sex, age and ethnicity) as well as history of treatment (type of psychotropic drug and treatment 150 duration). In order to preserve homogeneity of the samples, only patients treated up to 24 months were 151 taken into account in combined (i.e discovery plus replication) psychiatric sample analyses.
152
Statistical analysis
153
Psychiatric Samples 154 tests was applied. Eventually, differences in sample size might be due to missing genotypes and/or 158 covariates. First, exploratory analyses were conducted to explore differences in BMI between genetic 159 groups in the three psychiatric samples using Mann-Whitney U non parametric test. To fit a longitudinal 160 model on the BMI trend, due to complex and non-linear BMI evolution in time and presence of multiple 161 observations per individual which introduces interdependence among observations, a Generalized
162
Additive Mixed Model (GAMM) was used to assess the association of genetic polymorphism with BMI 163 adjusted by sex, age, treatment and treatment duration. This allowed a smooth trend for the response in 164 time based on multiple observations for each patient (using a thin plate regression spline basis). A 165 random effect at the subject level was also introduced to take the dependence structure of observed data 166 into account. 33 The GAMMs were fitted using the mgcv package of R (settings were fixed at package 167 defaults). To be more conservative, the uncertainty of estimated parameters was assessed by 1'000 168 bootstraps on individuals. For those p-values lower than 0.001, 10'000 bootstraps were performed 169 whenever possible. Multivariate analysis used the same methodology as previously described for the 170 upstream CRTC1 gene: 11 It was first conducted in the discovery sample and the significant results were 171 tested for replication in the two replication samples. In fitted longitudinal models, stratification by sex, and 172 in some cases by age, was applied when analyzing all samples together. Also, analyzes on WC and on 13 conducted for these polymorphisms. Finally it should be mentioned that preliminary analysis on PCK1 177 haplotypes and BMI for the 3 SNPs that formed a haplotype block (i.e. rs11552145, rs707555 and 178 rs8123020) showed no significant results (results not shown). 179
Population-Based Samples 180
Significant results from PCK1 polymorphisms in the discovery sample (i.e. rs6070157, proxy of 181 rs11552145; r 2 =0.99 and rs2071023) were further tested for replication in the three population samples 182 (CoLaus, GIANT and Global Lipids Genetics Consortium).
183
The associations of PCK1 polymorphisms with adiposity markers such as BMI, WC, fat mass and lipid 184 factors were analyzed using multiple linear regression with additive model in which potential confounding 
195
Association of PCK1 polymorphisms with BMI in psychiatric populations 196 Multivariate analyses were first conducted in the discovery sample for the four SNPs ( 
264
Japanese populations 20, 37 concluding that carriers of the minor allele (GG) were at risk of developing 265 T2DM, whereas no significant findings were found in German or Danish Caucasian populations. 18, 21
266
Finally, a case series study conducted in 3 Maltese women found that those who developed GDM carried 267 the homozygous variant allele, but these results must be replicated in larger cohorts. 38 In the present 268 study, no association was found between rs2071023 and BGL, although the diabetes phenotype was not 269 assessed. Additionally, and consistent with our results, another PCK1 polymorphism (rs707555) showed 270 no significant association with anthropometric traits such as WC, weight and fat mass or BMI. 22, 39
271
Analyses were conducted in the combined discovery and replication samples for treatment duration up to 272 24 months. Different effect sizes, detected in the discovery versus the replication samples, could be 273 explained by lower prevalence of obesity at baseline and shorter treatment durations in the discovery 274 sample (Table S- 
277
Of note, in the present study as in previous genetic studies, genetically explained variances of BMI are 278 quite low suggesting that BMI and metabolic features are influenced by multiple genetic factors as 279 previously described in the literature. 4 However, in the present study, rs11552145 was strongly 280 associated with BMI in the subgroup of women younger than 45 years and the observed difference in BMI between genotypes is of clinical significance. This result is in agreement with our previous study showing 282 that the association between a polymorphism of CRTC1 (an upstream gene of PCK1) and BMI was 283 higher in women younger than 45 years as compared to non-gender stratified sample. 11 In addition, a 284 positive correlation was found between PCK1 mRNA expression levels and BMI in a study conducted 285 with non-menopausal women. 15 Other pharmacogenetic studies also highlighted the importance of 286 stratifying by sex. 41, 42 This finding could be tentatively explained by the influence of estrogen circulating 287 levels on energy balance. 43 Thus, a lack of estrogen in mice was related to obesity, decreasing fasting 288 blood glucose levels, activating AMPK and reducing the expression of gluconeogenic genes, such as 289 PCK in the liver. 44, 45 However, this hypothesis could not be tested in our samples as estrogen circulating 290 levels were not measured.
291
In order to assess the contribution of PCK1 and CRTC1 polymorphisms on BMI, analyses combining both 292 SNPs were conducted. An additive association with BMI was observed over treatment duration among 293 carriers of CRTC1 rs3746266 G-allele and PCK1 rs11552145 AA genotype which had lower BMI when 294 compared to the reference group. As described elsewhere, 46 PCK family genes contain in their promoter 295 region a CREB-regulated element binding site where CRTC1 binds, enhancing PCK expression. In the 296 present study, the strongest associations were found among psychiatric population under psychotropic 297 treatment which could be explained by the additive effect between PCK1 and CRTC1 genes and 298 psychotropic drugs. In particular, CRTC1 is modulated, among other mechanisms, by adenosine 299 monophosphate protein kinase (AMPK) which is increased by antipsychotics. 47 Besides, several 300 polymorphisms on the AMPK gene, showed an association with weight gain induced by antipsychotics. 48 
301
AMPK has also been related to gluconeogenesis modulation. 49 Another study conducted in rats showed 302 that olanzapine increased the mRNA levels of glucose-6-phosphatase in the liver. 
307
Finally, in our sample, higher associations were found among psychiatric patients rather than in general 
311
Some limitations of the present study must be mentioned. Firstly, patients were not drug naive, therefore,
312
we could not assess whether the association between the polymorphisms and BMI or other phenotypes 313 was influenced by the psychiatric illness itself and/or by the psychotropic treatment. Secondly, although 314 the main inclusion criteria for patients in the present study was that they were receiving psychotropic 315 drugs known to induce weight gain (i.e aripiprazole, amisulpride, clozapine, olanzapine, quetiapine, and/or somatic drugs) were prescribed, the influence of which could not be evaluated. This study was 318 conducted in Caucasians, thus results cannot be extrapolated to other ethnicities. Not all tagging SNPs 319 could be tested due to limited availability of the genotypes. In addition, no significant associations with 320 BMI were found for the two other tested SNPs (rs707555 and rs8123020), either because of a lack of 321 effect or a lack of power due to the low MAF. Further replications of this study should increase sample 322 size in order to test low MAF polymorphisms and to increase the coverage of PCK1 gene by including 323 other tagging SNPs. Finally, variants obtained through GWAS should be also considered in further 324 analysis, in particular those on gluconeogenic pathway. It has thus been recently shown that PCK1 325 expression is regulated by CAMK1D, 52 a gene previously related to diabetes in GWAS. 53 
326
In conclusion, this is the first study investigating the association of PCK1 polymorphisms with BMI and 327 other metabolic traits in psychiatric populations. Higher associations were found in psychiatric patients # For current BMI, only significant findings in the discovery sample were further tested for replication. The same SNPs were also tested for replication at the baseline BMI. *Only patients treated for up to 24 months. 
